Finding a Place for Interleukin-1 Inhibitors in the Treatment of Rheumatologic Diseases

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|21|17|2198-2205

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.21, Iss.17, 2015-05, pp. : 2198-2205

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adverse effects of golimumab in the treatment of rheumatologic diseases

By Yang Hong   Kavanaugh Arthur  

Expert Opinion on Drug Safety, Vol. 13, Iss. 1, 2014-01 ,pp. : 103-112

Informa Healthcare

Access to resources Recommend Favorite

TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 3, 2009-09 ,pp. : 295-314

Bentham Science Publishers

Access to resources Recommend Favorite

An Overview of Interleukin-1 Receptor Antagonist, Anakinra, in the Treatment of Cutaneous Diseases

By  

Current Clinical Pharmacology, Vol. 7, Iss. 4, 2012-11 ,pp. : 271-275

Bentham Science Publishers

Access to resources Recommend Favorite

Oseltamivir: finding a place in the influenza treatment arena

By  

Inpharma, Vol. 1, Iss. 1248, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Metalloprotein Inhibitors for the Treatment of Human Diseases

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 4, 2016-02 ,pp. : 384-13

Bentham Science Publishers

Access to resources Recommend Favorite